Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03220724 · ClinicalTrials.gov registry record · Phase 1
Evaluating the Safety and Immunogenicity of EnvSeq-1 and CH505 M5 gp120 Envs Adjuvanted With GLA-SE in Healthy, HIV-Uninfected Adults
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 117
- Enrollment target
NCT03220724 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 117 participants.
The verdict
NCT03220724, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 117 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of EnvSeq-1 and CH505 M5 gp120 Envs adjuvanted with GLA-SE in healthy, HIV-uninfected adults.
Interventions
- BIOLOGICAL GLA-SE adjuvant
- BIOLOGICAL CH505TF
- BIOLOGICAL CH505w53
- BIOLOGICAL CH505w78
- BIOLOGICAL CH505 M5
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2017-08-22 |
| Est. Completion | 2023-03-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03220724
The ClinicalTrials.gov registry entry for NCT03220724 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which GLA-SE adjuvant is the first listed.
NCT03220724 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03220724 about?
NCT03220724 is a clinical study titled "Evaluating the Safety and Immunogenicity of EnvSeq-1 and CH505 M5 gp120 Envs Adjuvanted With GLA-SE in Healthy, HIV-Uninfected Adults". The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of EnvSeq-1 and CH505 M5 gp120 Envs adjuvanted with GLA-SE in healthy, HIV-uninfected adults.
What is the current status of trial NCT03220724?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 117 participants. The study started on 2017-08-22. Estimated completion is 2023-03-21.
What interventions are being tested in trial NCT03220724?
The interventions under investigation include: GLA-SE adjuvant (BIOLOGICAL), CH505TF (BIOLOGICAL), CH505w53 (BIOLOGICAL), CH505w78 (BIOLOGICAL), CH505 M5 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03220724?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.